LXRX News & Events

Lexicon Pharmaceuticals announced that results of a post hoc analysis of clinical data evaluating the impact of kidney function on the long-term efficacy and safety of sotagliflozin on people with type 1 diabetes will be delivered as a short oral presentation tomorrow, March 12, during the 19th International Conference on Advanced Technologies & Treatments for Diabetes. The congress is being held March 11-14, 2026, in Barcelona, Spain. "Recognizing that a patient's kidney function can impact the efficacy of SGLT inhibitors, we conducted this post hoc analysis of clinical data from two identically-designed trials in patients with type 1 diabetes and were encouraged to find that treatment with sotagliflozin resulted in improvements in multiple efficacy measures after one year in both those with normal kidney function and those with mildly reduced kidney function," said Craig Granowitz, M.D., Ph.D., Lexicon's senior vice president and chief medical officer. "Not only was sotagliflozin shown to improve cardiometabolic parameters in this patient population, but it also reduced clinically important hypoglycemia events, which are a leading cause of acute mortality and morbidity and can be life-threatening." Lexicon remains on track to resubmit the New Drug Application for ZYNQUISTA glycemic control in patients with type 1 diabetes in 2026 based upon U.S. Food and Drug Administration feedback and additional clinical data received to date from the STENO1 study

Reports Q4 revenue $5.5M, consensus $3.14M. As of December 31, 2025, Lexicon had $125.2M in cash, investments and restricted cash, as compared to $238.0M in cash and investments as of December 31, 2024."The Q4 marked the completion of an incredible year for Lexicon," said Mike Exton, Lexicon's CEO and director. "We made substantial progress on all aspects of the business by advancing our pipeline programs, establishing strong development and commercialization agreements with leading global collaborators, working closely with regulators, and remaining operationally efficient. As a result, we have begun 2026 with tremendous momentum and are well-positioned to successfully execute on multiple important catalysts ahead."